🚀 CC Diagnostics & partners receive a €600K subsidy grant! Thanks to the support of Samenwerkingsverband Noord-Nederland (SNN) our team can further develop the Methica CC kit to solve the current challenges in cervical cancer screening. 🔬 With our trusted partners UMCG, MolGen and IQ Products we will bring molecular screening to the next level.

CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? 97% sensitivity for cancer detection, outperforming the pap smear by 21%—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.

🎉We’re thrilled to announce that CC Diagnostics was selected as one of 30 trailblazing European start-ups in the prestigious EIT Catapult! With this program's support, we’re more energized than ever to advance cervical cancer screening and make a global impact on women’s healthcare.